Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Express Scripts
Johnson and Johnson
Moodys
AstraZeneca

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR TRESIBA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Tresiba

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01984372 ↗ Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba® Completed Novo Nordisk A/S 2013-11-06 This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin therapy under normal clinical practice conditions. A total of 4000 patients will be enrolled to investigate long term (3 years of treatment) safety of Tresiba® and additional 2000 patients will be enrolled to assess the safety in an early stage of the PMS more precisely. At the time of enrolment the patients will be randomly allocated to either 3 years or 6 months observation group.
NCT02117622 ↗ A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India Completed Novo Nordisk A/S 2015-07-24 This study is conducted in Asia. The aim of the study is to evaluate long term safety and efficacy of Tresiba® (insulin degludec) in patients with diabetes mellitus in routine clinical practice in India.
NCT02192450 ↗ Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia Completed Aarhus University Hospital Phase 4 2015-01-01 The purpose of this study is to determine whether insulin degludec compared to insulin glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the greatest potential benefit from optimised insulin treatment, which are patients with type 1 diabetes and high risk of nocturnal severe hypoglycaemia.
NCT02192450 ↗ Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia Completed Copenhagen University Hospital, Denmark Phase 4 2015-01-01 The purpose of this study is to determine whether insulin degludec compared to insulin glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the greatest potential benefit from optimised insulin treatment, which are patients with type 1 diabetes and high risk of nocturnal severe hypoglycaemia.
NCT02192450 ↗ Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia Completed Hvidovre University Hospital Phase 4 2015-01-01 The purpose of this study is to determine whether insulin degludec compared to insulin glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the greatest potential benefit from optimised insulin treatment, which are patients with type 1 diabetes and high risk of nocturnal severe hypoglycaemia.
NCT02192450 ↗ Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia Completed Odense University Hospital Phase 4 2015-01-01 The purpose of this study is to determine whether insulin degludec compared to insulin glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the greatest potential benefit from optimised insulin treatment, which are patients with type 1 diabetes and high risk of nocturnal severe hypoglycaemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tresiba

Condition Name

Condition Name for Tresiba
Intervention Trials
Diabetes Mellitus, Type 2 6
Diabetes Mellitus, Type 1 5
Type 1 Diabetes Mellitus 5
Diabetes 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tresiba
Intervention Trials
Diabetes Mellitus 19
Diabetes Mellitus, Type 2 12
Diabetes Mellitus, Type 1 11
Hypoglycemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tresiba

Trials by Country

Trials by Country for Tresiba
Location Trials
United States 33
India 14
United Kingdom 5
Italy 4
Spain 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tresiba
Location Trials
California 3
Washington 3
Texas 2
Georgia 2
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tresiba

Clinical Trial Phase

Clinical Trial Phase for Tresiba
Clinical Trial Phase Trials
Phase 4 12
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tresiba
Clinical Trial Phase Trials
Completed 15
Recruiting 3
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tresiba

Sponsor Name

Sponsor Name for Tresiba
Sponsor Trials
Novo Nordisk A/S 9
Sanofi 4
University of Washington 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tresiba
Sponsor Trials
Other 20
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Colorcon
Merck
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.